Xirestomig

西雷苏米单抗

Report date: 2024/03/27 13:26:47

Base Information

Drug NameXirestomig
Drug Alias NameATG-101ATG101YN051
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulantsProgrammed death-ligand 1 blockers +[4] 
TargetsProgrammed death-ligand 1Tumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumoursHematologic NeoplasmsLymphoma, B-Cell +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesThe Origin Cell Technology Group Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAntengene Corp LtdAntengene Corporation (Hong Kong) LtdAntengene Corporation (Shanghai) Ltd
Inactive CompaniesDeqi (Hangzhou) Biological Co LtdAntengene Corporation Co Ltd
Active IndicationsSolid tumoursLymphoma, Non-Hodgkin
Inactive IndicationsHematologic NeoplasmsLymphoma, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A